Highlight Therapeutics closes a €15 million funding round led by Buenavista

by Highlight Therapeutics

Highlight Therapeutics is a Spanish biotechnology company specialising in immuno-oncology, focused on the development of innovative cancer therapies. Its lead investigational compound, BO-112, is a do...

Read more

New clinical trial targets the most common form of skin cancer with a compound based on CNIO discoveries

by CNIO - Centro Nacional de Investigaciones Oncológicas

Highlight Therapeutics and CNIO are collaborating to proof BO-112 effectiveness against the most common form of skin cancer, which is linked to sun exposure and is on the rise.

Read more

Highlight Therapeutics y Pivotal trabajan conjuntamente en el tratamiento del melanoma y lanzan un ensayo clínico fase IIa para determinar la seguridad y eficacia de BO-112

by Pivotal

Highlight Therapeutics,(“Highlight”), una compañía biofarmacéutica clínica que desarrolla tratamientos antitumorales basados en RNA, y Pivotal, una CRO de implantación Europea y que ofrece se...

Read more

Highlight Therapeutics & Pivotal advance into a Phase IIa trial to examine Gastro-Intestinal cancer therapy

by Pivotal

Highlight Ther​apeutics, (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, and Pivotal, a Europe-wide full-service CRO, today announced tha...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream